Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)

Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)

US Patent 5858969 · Granted Jan 12, 1999

Estimated economic value: $2,494,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Nucleic acids encoding anti-TREM-1 antibodies2024
Anti-TREM-1 antibodies and uses thereof2024
Chimeric antigen receptors targeting TIM-12023
Fast-off rate serum albumin binding fibronectin type III domains2022
Serum albumin-binding fibronectin type III domains2021
Antibodies that bind human CD27 and uses thereof2021
Anti-TREM-1 antibodies and uses thereof2021
Serum albumin binding molecules2021
Fast-off rate serum albumin binding fibronectin type III domains2020
Serum albumin-binding fibronectin type III domains2019
Serum albumin binding molecules2019
Treatment of chronic nephropathies using soluble complement receptor type I (sCR2017